NCT06533358View on ClinicalTrials.gov

A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

July 31, 2025

Conditions
Acute Coronary Syndrome
Interventions
DRUG

MT1002 Injection

MT1002 is infused once only, once for 4h. MT1002 is for subjects with acute coronary syndrome undergoing PCI

Trial Locations (2)

100029

RECRUITING

Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing

712000

RECRUITING

Xianyang Hospital, Yan'an University, Xi'an

All Listed Sponsors
lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY